EX-23.1 7 g06286n8exv23w1.htm EX-23.1 CONSENT OF KPMG LLP. EX-23.1 Consent of KPMG LLP
 

EXHIBIT 23.1
 
Consent of Independent Registered Public Accounting Firm
 
The Board of Directors
Cumberland Pharmaceuticals, Inc.:
 
We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus. Our report refers to a change in accounting for stock-based compensation in 2006.
 
KPMG
 
Nashville, Tennessee
February 1, 2008